Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hematologic malignancy

Hematologic malignancy

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hematologic malignancy

23 trials tracked for Hematologic malignancy.

23Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 8 Phase 1 3 Other / NA 12
  1. Phase 2 Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Completed
  2. Phase 2 A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Completed
  3. Phase 2 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant Completed
  4. Phase 2 Phase II Maraviroc for GVHD Prevention Completed
  5. Phase 2 Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) Completed
  6. Phase 2 Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Completed
Show 17 more trials
  1. Phase 2 Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Completed
  2. Phase 2 A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) Completed
  3. Phase 1 Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels Completed
  4. Phase 1 Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer Completed
  5. Phase 1 Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer Completed
  6. N/A Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor Completed
  7. N/A Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) Completed
  8. N/A Proof-of-Concept Trial of a Positive Psychology Intervention for Caregivers of Patients Undergoing HSCT Completed
  9. N/A Removing Transfusion Dependence as a Barrier to Hospice Enrollment Completed
  10. N/A Positive Psychology Intervention In HSCT Completed
  11. N/A A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients Completed
  12. N/A Lighting Intervention for Cancer-related Fatigue Completed
  13. N/A Patient-Centered Care for the Older Adult With Hematologic Malignancy Completed
  14. N/A A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP) Completed
  15. N/A Besponsa Post Marketing Surveillance Study Completed
  16. N/A Mindfulness and CBT for Sleep Completed
  17. N/A A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Somatic passenger mutation burden is associated with hematologic malignancy and mortality in large genomic cohorts
Genetics & Precision Medicine Meta-analysis
Somatic passenger mutation burden is associated with hematologic malignancy and mortality in large genomic cohorts Genetic markers linked to blood cancer and higher mortality risk
This meta-analysis of 791,067 whole-genome sequences identifies 81 loci, including 42 novel loci, associated with somatic passenger mutation…
New research identifies specific genetic markers that link a high burden of mutations to blood cancer and increased risk of death.
medRxiv Aug 30, 2026